Analyst Price Target is $18.67
▲ +242.51% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for CalciMedica in the last 3 months. The average price target is $18.67, with a high forecast of $22.00 and a low forecast of $14.00. The average price target represents a 242.51% upside from the last price of $5.45.
Current Consensus is
Buy
The current consensus among 3 investment analysts is to buy stock in CalciMedica. This Buy consensus rating has held steady for over two years.
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
Read More